Michelle Sexton

Title(s)Assistant Adjunct Professor, Anesthesiology
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Bastyr University, Seattle, WAND06/2008Naturopathic Medicine
    University of Washington, Seattle, WApostdoctoral fellowship09/2011cannabinoid pharmacology

    Collapse Overview 
    Collapse Overview
    Dr. Sexton received her Doctor of Naturopathy degree from Bastyr University and followed this with an individual Postdoctoral Fellowship at University of Washington in the Department of Pharmacology. At UCSD, Dr. Sexton is involved in education and development of research in the field of medical cannabis.

    Dr. Sexton's clinical research focuses on the role of the endocannabinoid system in health and disease. She is an active investigator in several ongoing research projects researching medical cannabis in neuropathic pain, migraine, opioids tapering and effects across many disease states.

    Collapse Research 
    Collapse Research Activities and Funding
    Medical Cannabis Use in Patients with Chronic Pain
    Sep 1, 2018 - Aug 31, 2019
    Role: PI
    Role Description: The purpose of this study is to retrospectively review the medical charts of Pain Clinic patients receiving chronic opioids. We will compare patients with various pain diagnoses who did/did not receive a medical cannabis recommendations as an adjuvant to the opioids. From the medical chart we will record whether there were changes in pain and relief scores over time, changes in anxiety or depression over time and whether patients tapered down on their opiates or other associated medications (such as anxiolytics or antidepressants and sleep medications). We will use a morphine milligram equivalent conversion to standardize the ability to quantify opiates medications. We plan to conduct a follow-up telephone interview with the patients who did receive a recommendation for medical cannabis to determine how many patients continue to use medical cannabis, methods of administration (inhaled, oral) and any information on the potency of the products they are using (mg doses of THC and/or CBD and % THC/CBD potency of flower material).
    Cannabidiol in Pain Symptom Management
    Albert Einstein School of Medicine Aug 1, 2018
    Role: Co-Investigator
    Role Description: The goal of this study is to gather information thatwe hope will provide health care providers withmore knowledge about how and when to recommend patients use Cannabidiol (CBD). Cannabidiol (CBD) is being used with increased frequency by medical cannabis patients across the country. CBD is felt to have many possible therapeutic benefits, but there is very little data inthe medical literature from controlled clinical trials that allows health care providers to know how to advise people on how to use CBD and for what conditions and symptoms it may work best.

    Collapse ORNG Applications 
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Medical Cannabis for Migraine & Pain . Practical Neurology . 2021. . View Publication.
    2. Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients' Perspectives and Attitudes. J Pain Res. 2021; 14:1241-1250. Schilling JM, Hughes CG, Wallace MS, Sexton M, Backonja M, Moeller-Bertram T. PMID: 33981161.
      View in: PubMed   Mentions:
    3. The Management of Cancer Symptoms and Treatment-Induced Side Effects with Cannabis of Cannabinoids. Journal of the National Cancer Institute. 2021. .
    4. Cannabis: An Emerging Treatment for Common Symptoms in Older Adults. J Am Geriatr Soc. 2021 01; 69(1):91-97. Yang KH, Kaufmann CN, Nafsu R, Lifset ET, Nguyen K, Sexton M, Han BH, Kim A, Moore AA. PMID: 33026117.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    5. Medical Cannabis: A New Old Tool for Palliative Care. J Altern Complement Med. 2020 Sep; 26(9):776-778. Kogan M, Sexton M. PMID: 32924552.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    6. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence. J Altern Complement Med. 2020 Jun; 26(6):444-448. Sexton M. PMID: 32380847.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsPHPublic Health
    7. Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey. BMC Fam Pract. 2019 12 14; 20(1):174. Corroon J, Sexton M, Bradley R. PMID: 31837706.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Allostatic load and the cannabinoid system: implications for the treatment of physiological abnormalities in post-traumatic stress disorder (PTSD). CNS Spectr. 2020 12; 25(6):743-749. Lohr JB, Chang H, Sexton M, Palmer BW. PMID: 31303187.
      View in: PubMed   Mentions: 2     Fields:    
    9. A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age. J Altern Complement Med. 2019 Mar; 25(3):326-335. Sexton M, Cuttler C, Mischley LK. PMID: 30383388.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    10. Driving Under the Influence of Cannabis: An Examination of Driving Beliefs and Practices of Medical and Recreational Cannabis Users Across the United States. Cannabis. 2018; 2(1):1-13. .
    11. Evaluation of Cannabinoid and Terpenoid Content: Cannabis Flower Compared to Supercritical CO2 Concentrate. Planta Med. 2018 Mar; 84(4):234-241. Sexton M, Shelton K, Haley P, West M. PMID: 28926863.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    12. Cannabis as a substitute for prescription drugs - a cross-sectional study. J Pain Res. 2017; 10:989-998. Corroon JM, Mischley LK, Sexton M. PMID: 28496355.
      View in: PubMed   Mentions:
    13. Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users. Cannabis Cannabinoid Res. 2016; 1(1):166-175. Cuttler C, Mischley LK, Sexton M. PMID: 28861492.
      View in: PubMed   Mentions:
    14. A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy. Cannabis Cannabinoid Res. 2016; 1(1):131-138. Sexton M, Cuttler C, Finnell JS, Mischley LK. PMID: 28861489.
      View in: PubMed   Mentions:
    15. Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology. 2014 Oct; 22(5):295-303. Sexton M, Cudaback E, Abdullah RA, Finnell J, Mischley LK, Rozga M, Lichtman AH, Stella N. PMID: 25135301.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    16. Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis. Inflammopharmacology. 2013 Jun; 21(3):253-9. Sexton M, Silvestroni A, Möller T, Stella N. PMID: 22492174.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    17. NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening. Chem Biol. 2011 May 27; 18(5):563-8. Sexton M, Woodruff G, Horne EA, Lin YH, Muccioli GG, Bai M, Stern E, Bornhop DJ, Stella N. PMID: 21609837.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    18. Binding of NIR-conPK and NIR-6T to astrocytomas and microglial cells: evidence for a protein related to TSPO. PLoS One. 2009 Dec 18; 4(12):e8271. Sexton M, Woodruff G, Cudaback E, Kreitzer FR, Xu C, Lin YH, Möller T, Bai M, Manning HC, Bornhop D, Stella N. PMID: 20020060.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    19. MBC94, a conjugable ligand for cannabinoid CB 2 receptor imaging. Bioconjug Chem. 2008 May; 19(5):988-92. Bai M, Sexton M, Stella N, Bornhop DJ. PMID: 18444670.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    20. A peripheral benzodiazepine receptor targeted agent for in vitro imaging and screening. Bioconjug Chem. 2006 May-Jun; 17(3):735-40. Manning HC, Smith SM, Sexton M, Haviland S, Bai M, Cederquist K, Stella N, Bornhop DJ. PMID: 16704212.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    Michelle's Networks
    Concepts (91)
    Derived automatically from this person's publications.
    Co-Authors (4)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department